Technical Analysis for AWH - Aspira Women's Health Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 3.53 | 1.15% | 0.04 |
AWH closed up 1.15 percent on Thursday, April 18, 2024, on 31 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: May 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Weak + Overbought | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Weak, Overbought and Reversal Signs | Reversal | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Stochastic Reached Overbought | Strength | 1.15% | |
Weak + Overbought | Other | 1.15% | |
Wide Bands | Range Expansion | 1.15% | |
Overbought Stochastic | Strength | 1.15% |
Alert | Time |
---|---|
Possible NR7 | about 16 hours ago |
Down 2 % | about 17 hours ago |
Down 1% | about 17 hours ago |
Rose Above Previous Day's High | about 18 hours ago |
Up 2% | about 18 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Aspira Women’s Health Inc. (formerly known as Vermillion, Inc. Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1®plus combines our FDA-cleared products OVA1® and OVERA® to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and a more comprehensive genetic testing options with a gynecologic focus. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Clinical Medicine Oncology Healthcare Providers FDA Ovarian Cancer Genetic Testing Patient Management Analytical Solutions Gynaecological Cancer Gynaecology
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Clinical Medicine Oncology Healthcare Providers FDA Ovarian Cancer Genetic Testing Patient Management Analytical Solutions Gynaecological Cancer Gynaecology
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.75 |
52 Week Low | 2.3087 |
Average Volume | 24,983 |
200-Day Moving Average | 3.99 |
50-Day Moving Average | 3.77 |
20-Day Moving Average | 3.22 |
10-Day Moving Average | 3.23 |
Average True Range | 0.32 |
RSI (14) | 54.55 |
ADX | 22.74 |
+DI | 18.68 |
-DI | 14.92 |
Chandelier Exit (Long, 3 ATRs) | 2.85 |
Chandelier Exit (Short, 3 ATRs) | 3.47 |
Upper Bollinger Bands | 3.87 |
Lower Bollinger Band | 2.57 |
Percent B (%b) | 0.74 |
BandWidth | 40.64 |
MACD Line | -0.08 |
MACD Signal Line | -0.18 |
MACD Histogram | 0.1022 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.79 | ||||
Resistance 3 (R3) | 3.77 | 3.67 | 3.74 | ||
Resistance 2 (R2) | 3.67 | 3.61 | 3.68 | 3.73 | |
Resistance 1 (R1) | 3.60 | 3.56 | 3.55 | 3.62 | 3.71 |
Pivot Point | 3.50 | 3.50 | 3.48 | 3.51 | 3.50 |
Support 1 (S1) | 3.43 | 3.44 | 3.38 | 3.45 | 3.35 |
Support 2 (S2) | 3.33 | 3.39 | 3.34 | 3.33 | |
Support 3 (S3) | 3.26 | 3.33 | 3.32 | ||
Support 4 (S4) | 3.28 |